Less is more? De-intensification of therapy for early-stage HER2-positive breast cancer

被引：1
|
作者：
Mathew, Aju [1 ]
Brufsky, Adam [2 ]
机构：
[1] Univ Kentucky, Markey Canc Ctr, Lexington, KY USA
[2] Univ Pittsburgh, Med Ctr, Magee Womens Hosp, Pittsburgh, PA 15241 USA
来源：
LANCET ONCOLOGY | 2017年 / 18卷 / 04期
关键词：
OPEN-LABEL; TRASTUZUMAB; MULTICENTER; TRIAL;
D O I：
10.1016/S1470-2045(17)30150-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：428 / 429
页数：3
相关论文
共 50 条
  • [21] Ultra-Short Fraction Schedules as Part of De-intensification Strategies for Early-Stage Breast Cancer
    Chirag Shah
    Martin Keisch
    Atif Khan
    Douglas Arthur
    David Wazer
    Frank Vicini
    Annals of Surgical Oncology, 2021, 28 : 5005 - 5014
  • [22] Treatment of Lymph Node-Negative, Early-Stage HER2-Positive Breast Cancer
    Oguz, Arzu
    Keskin, Gul Sema
    Colak, Dilsen
    Altundag, Ozden
    Akcali, Zafer
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (06) : 639 - +
  • [23] Ultra-Short Fraction Schedules as Part of De-intensification Strategies for Early-Stage Breast Cancer
    Shah, Chirag
    Keisch, Martin
    Khan, Atif
    Arthur, Douglas
    Wazer, David
    Vicini, Frank
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (09) : 5005 - 5014
  • [24] Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancer
    Marin-Aguilera, M.
    Jares, P.
    Sanfeliu, E.
    Villacampa, G.
    Hernandez-lllan, E.
    Martinez-Puchol, A. I.
    Shankar, S.
    Gonzalez-Farre, B.
    Waks, A. G.
    Braso-Maristany, F.
    Pardo, F.
    Manning, D. K.
    Abery, J. A.
    Curaba, J.
    Moon, L.
    Gordon, O.
    Galvan, P.
    Wachirakantapong, P.
    Castillo, O.
    Nee, C. M.
    Blasco, P.
    Senevirathne, T. H.
    Sirenko, V.
    Martinez-Saez, O.
    Aguirre, A.
    Krop, I. E.
    Li, Z.
    Spellman, P.
    Metzger Filho, O.
    Polyak, K.
    Michaels, P.
    Puig-Butille, J. A.
    Vivancos, A.
    Matito, J.
    Buckingham, W.
    Perou, C. M.
    Villagrasa-Gonzalez, P.
    Prat, A.
    Parker, J. S.
    Pare, L.
    ESMO OPEN, 2024, 9 (03)
  • [25] Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines
    Anne Julienne Genuino
    Usa Chaikledkaew
    Anna Melissa Guerrero
    Thanyanan Reungwetwattana
    Ammarin Thakkinstian
    BMC Health Services Research, 19
  • [26] Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines
    Genuino, Anne Julienne
    Chaikledkaew, Usa
    Guerrero, Anna Melissa
    Reungwetwattana, Thanyanan
    Thakkinstian, Ammarin
    BMC HEALTH SERVICES RESEARCH, 2019, 19 (01)
  • [27] Neratinib for the treatment of HER2-positive early stage breast cancer
    Echavarria, Isabel
    Lopez-Tarruella, Sara
    Marquez-Rodas, Ivan
    Jerez, Yolanda
    Martin, Miguel
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (08) : 669 - 679
  • [28] Optimal treatment of early stage HER2-positive breast cancer
    Pernas, Sonia
    Barroso-Sousa, Romualdo
    Tolaney, Sara M.
    CANCER, 2018, 124 (23) : 4455 - 4466
  • [29] Personalized treatment for early stage HER2-positive breast cancer
    Prat, A.
    CANCER RESEARCH, 2021, 81 (04)
  • [30] A prognostic miRNA based signature in early-stage HER2-positive breast cancer patients.
    Adam-Artigues, Anna
    Angel Beltran, Miguel
    Antonio Carbonell-Asins, Juan
    Zuniga, Sheila
    Moragon, Santiago
    Martinez, Maite
    Hernando, Cristina
    Burgues, Octavio
    Rojo, Federico
    Albanell, Joan
    Lluch, Ana
    Bermejo, Begona
    Eroles, Pilar
    Miguel Cejalvo, Juan
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345